Domenico "Dinko" Valerio (born 1956)
Wikipedia 🌐 NONE
....
ASSOCIATIONS
Alex Jan "Lex" van der Eb (born 1934) ...
"In 1995, together with [Domenico "Dinko" Valerio (born 1956)], [Alex Jan "Lex" van der Eb (born 1934)] created the PER.C6 cell line with enhanced traceability compared to the HEK 293 line, this time coming from retinal cells.[4] The goal of [Domenico "Dinko" Valerio (born 1956)], was to use it for gene therapy but this was ultimately unsuccessful. In contrast to HEK 293 the PER.C6 cell line was patented by Leiden University and [IntroGene] (later [Crucell]) and used commercially." [HK00B5][GDrive]
Dr. Robert Wallace Malone (born 1959) ...
Robert Malone claims to have worked with Valerio, when at the Salk ... See 2021 (June) Dark Horse Podcast : "Saving the world in 3 easy steps" :
Robert Malone: "[...] The guy that founded Crucell was the senior post doc in the gene therapy lab that I worked at the [Salk Institute]. [...] Okay, Dinko Valerio and he came to me once few years after Crucell had been founded, which was a gene therapy company based on adenoviral vectors. And he said to me, “Robert, you’re right. We should use this for vaccines.” [...] . And he pivoted Crucell to being a vaccine company and the rest is history. It was bought by J & J and that is the basis for the J & J technology. Okay, it is explicitly a retooled gene therapy method applied to vaccines full-stop."
COMPANIES
LinkedIN for Dinko Valerio (captured April 11, 2023)
https://www.linkedin.com/in/dinko-valerio-9a402284/?originalSubdomain=nl
2023-04-11-linkedin-com-dinko-valerio.pdf
2023-04-11-linkedin-com-dinko-valerio-img-1.jpg
About
Domenico (Dinko) Valerio is a scientist-turned-entrepreneur, co-founder and Executive Chairman of Leyden Labs, a company targeting commonalities of respiratory viruses to protect against known and future viral outbreaks. He is also the founder and former CEO of Crucell, a biotechnology company specializing in vaccines. He further co-founded Galapagos Genomics and Venture Capital firm Aescap Venture. As a mentor of other entrepreneurs, Dinko co-founded ProQR Therapeutics (PRQR) where he is Chairman of the Board.
In 1992, Dinko was appointed professor of gene therapy at the University of Leiden, where he also received his Ph.D. with honors.
Experience
Leyden Labs
Co-founder & Executive Chairman / 2020 - Present · 3 yrs 4 mos / Leiden, South Holland, Netherlands
ProQR Therapeutics
Co-founder & Chairman of the Board / 2012 - Present · 11 yrs 4 mos
AESCAP Venture
Co-founder & managing partner / 2006 - 2016 · 10 yrs / Amsterdam, North Holland, Netherlands
Crucell
Founder & CEO / 1993 - 2004 · 11 yrs
Founder and CEO of Dutch biopharmaceutical company specializing in vaccines later acquired by Johnson & Johnson
Leiden University Medical Center
Professor of Gene Therapy (part-time) / 1992 - 2000 · 8 yrs
TNO Radiobiological Institute
Group leader Gene Therapy / 1987 - 1993 · 6 yrs / Rijswijk, South Holland, Netherlands
Salk Institute for Biological Studies
Postdoctoral Scientist / 1986 - 1987 · 1 yr / San Diego, California, United States
Genentech USA, Inc.
Visiting scientific specialist / 1985 · Less than a year / South San Francisco, California, United States
Real name Dominico
https://sciencebusiness.net/author/domenico-valerio
Domenico Valerio
Memo to entrepreneurs: Stay flexible
Don't fall in love with your technology, advises Dinko Valerio, a leading Dutch bio entrepreneur and VC.
09 May 2007
SEC filing -
born -
Dinko Valerio
August 3, 1956
https://proqr.gcs-web.com/node/8771/html
sec-filing-proqr-therapeutics.pdf
How Dinko Valerio became a Dutch biotech icon with Crucell, ProQR Therapeutics, & Leyden Labs
We wrap up season #2 of The Scale Lab with a special guest - Dinko Valerio, scientist-turned-entrepreneur; co-founder of Leyden Labs & ProQR Therapeutics; founder of Crucell; and startup mentor. In this episode, we discover the secrets of building a successful biotech venture and securing funding within the health sector. To all the healthtech founders out there - tune in for a highly valuable discussion full of founder learnings and advice.
https://wallmine.com/nasdaq/prqr/officer/1773962/dinko-valerio
2023-04-11-wallmine-com-officer-dinko-valerio.pdf
LAST UPDATED: 1 APRIL 2023 AT 11:00AM EST
Dinko Valerio Net Worth
Dinko Valerio biography
Dinko Valerio serves as Independent Chairman of the Supervisory Board of the Company. Dinko Valerio is one of our founders and currently serves as the chairman of our Supervisory Board. Mr. Valerio has served on our supervisory board since January 2014. Mr. Valerio is a scientist and an experienced biotech entrepreneur with experience in both public and private companies as CEO and board member. Mr. Valerio is founder and former CEO of Crucell N.V., a Dutch biotech company, and founder and former general partner of Aescap Venture, a life sciences venture capital firm. In 1999, Mr. Valerio was one of the founders of Galapagos Genomics N.V., a spinout from Crucell N.V. which develops novel mode of action medicines. In 2017 Mr. Valerio became a board member of Amylon Therapeutics B.V., an 80% owned affiliate of ProQR Therapeutics N.V. Adding to his corporate experience, Mr. Valerio was appointed professor in the field of gene therapy of the hematopoietic system at the University of Leiden in 1992. He received his Master of Science degree in Biology from the University of Amsterdam in 1982 and completed his Ph.D. in Molecular Genetics with Honors at the University of Leiden in 1986. Mr. Valerio also was a visiting scientific specialist at Genentech Inc., San Francisco in 1985 and a postdoctoral fellow at the Salk Institute, San Diego from 1986 to 1987. He is an author on more than 100 articles in peer-reviewed journals and an inventor on 11 patent-families.
What is the salary of Dinko Valerio?
As the Independent Chairman of the Supervisory Board of ProQR Therapeutics N.V, the total compensation of Dinko Valerio at ProQR Therapeutics N.V is $180,000. There are 2 executives at ProQR Therapeutics N.V getting paid more, with Daniel De Boer having the highest compensation of $2,265,000.
How old is Dinko Valerio?
Dinko Valerio is 63, he's been the Independent Chairman of the Supervisory Board of ProQR Therapeutics N.V since 2014. There are 1 older and 10 younger executives at ProQR Therapeutics N.V. The oldest executive at ProQR Therapeutics N.V is Dr. Naveed K. Shams M.D., Ph.D., 65, who is the Chief Scientific Officer.
https://www.marketscreener.com/business-leaders/Domenico-Valerio-05JW58-E/biography/
2023-04-11-marketscreener-com-domenico-valerio-05jw58-e.pdf
2023-04-11-marketscreener-com-domenico-valerio-05jw58-e-img-1.jpg
age 66 as of 2023 ... that means bday of 1957 ?
Age : 66
Public asset : 2,140,791 USD
Linked companies : ProQR Therapeutics N.V.
Summary
Founder of 5 different companies, including: Crucell NV, ProQR Therapeutics NV and Galapagos Genomics NV, Domenico Valerio is an entrepreneur and businessperson who has been at the helm of 6 different companies and currently holds the position of Chairman-Supervisory Board for ProQR Therapeutics NV (which he founded in 2014) and Chairman-Supervisory Board of Leyden Laboratories B.V. (which he founded).
He is also on the board of Biocartis SA (former Director) and Amylon Therapeutics BV and Managing Director at Stichting Administratiekantoor Endavit and Professor at the University of Leiden.
He previously occupied the position of General Partner at Aescap Venture Management BV (he founded the company in 2005) and Chief Executive Officer at Crucell NV (he founded the company in 2000).
Domenico Valerio received a graduate degree from the University of Amsterdam and a doctorate from the University of Leiden.
Current positions of Domenico Valerio
Name
Title
Since
(Biotechnology & Medical Research)
Chairman-Supervisory Board
2014
Stichting Administratiekantoor Endavit
Managing Director
-
Leyden Laboratories B.V.
Chairman-Supervisory Board
2020
Biocartis SA
Non-Executive Director
2012
Amylon Therapeutics BV
Member-Supervisory Board
2017
University of Leiden
Professor
1992
Holdings of Domenico Valerio
Name
Equities
%
Valuation
ProQR Therapeutics N.V. (PRQR)
(Biotechnology & Medical Research)
725,692
1.02%
2,140,791 USD
Domenico Valerio: Personal Network
Name
Linked companies
Biocartis SA
Biocartis SA
Leyden Laboratories B.V.
Amylon Therapeutics BV
Amylon Therapeutics BV
University of Leiden